Astra’s clodronate
Executive Summary
RPR acquring U.S. rights to the bone metabolism therapy, which it will develop in both new I.V. and oral forms. Rhone-Poulenc Rorer already markets the Astra product in France and will be launched in other European countries in the near-term. RPR concurrently is selling to Astra for cash five non-strategic hospital products: MVI, Aquasol A and E, Arm-a-Med and Arm-a-Vial. Deal is second non-strategic asset divestiture announced by RPR in
RPR acquring U.S. rights to the bone metabolism therapy, which it
will develop in both new I.V. and oral forms. Rhone-Poulenc Rorer
already markets the Astra product in France and will be launched in
other European countries in the near-term. RPR concurrently is
selling to Astra for cash five non-strategic hospital products:
MVI, Aquasol A and E, Arm-a-Med and Arm-a-Vial. Deal is second
non-strategic asset divestiture announced by RPR in |